stocks logo

BPMC

Blueprint Medicines Corp
$
129.500
+0.04(0.031%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
High
129.500
Open
129.500
VWAP
--
Vol
--
Mkt Cap
6.80B
Low
129.500
Amount
--
EV/EBITDA(TTM)
--
Total Shares
62.62M
EV
8.18B
EV/OCF(TTM)
--
P/S(TTM)
14.76
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
208.21M
+42.25%
--
--
191.05M
+49.04%
--
--
171.34M
+24.02%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Blueprint Medicines Corporation (BPMC) for FY2025, with the revenue forecasts being adjusted by -0.35% over the past three months. During the same period, the stock price has changed by 46.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.35%
In Past 3 Month
Stock Price
Go Up
up Image
+46.27%
In Past 3 Month
18 Analyst Rating
up Image
0.93% Upside
Wall Street analysts forecast BPMC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BPMC is 130.71 USD with a low forecast of 129.00 USD and a high forecast of 135.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
16 Hold
0 Sell
Hold
up Image
0.93% Upside
Current: 129.500
sliders
Low
129.00
Averages
130.71
High
135.00
Wells Fargo
Overweight -> Equal Weight
downgrade
$143 -> $129
2025-06-18
Reason
Wells Fargo downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $129, down from $143. The firm cites the pending takeover by Sanofi (SNY) for the downgrade.
Morgan Stanley
Equal Weight
maintain
$102 -> $129
2025-06-05
Reason
Morgan Stanley raised the firm's price target on Blueprint Medicines (BPMC) to $129 from $102 and keeps an Equal Weight rating on the shares. The key upside risk to the firm's Equal Weight rating has played out with Sanofi's (SNY) announced acquisition of Blueprint for $129 per share plus a non-tradeable CVR of up to $6 per share, the analyst tells investors in a research note.
UBS
David Lai
Neutral
maintain
$88 -> $129
2025-06-05
Reason
UBS analyst David Lai raised the firm's price target on Blueprint Medicines (BPMC) to $129 from $88 and keeps a Neutral rating on the shares after Sanofi (SNY) announced its intention to acquire Blueprint for up to $9.5B including a contingent value right.
Citi
Sell -> Neutral
upgrade
$83 -> $129
2025-06-04
Reason
Citi upgraded Blueprint Medicines (BPMC) to Neutral from Sell with a price target of $129, up from $83, following the announcement that Blueprint will be acquired by Sanofi (SNY) in a cash transaction of $129 per share plus contingent value rights considerations for pipeline asset BLU-80. At this time, Citi does not expect regulatory hurdles or competitive bids to impact the transaction.
Citizens JMP
Reni Benjamin
Outperform -> Market Perform
downgrade
2025-06-03
Reason
Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines (BPMC) to Market Perform from Outperform without a price target given the proposed acquisition by Sanofi (SNY). Shareholders should vote in favor of this acquisition as the offer is fair and competing bids are unlikely, the analyst tells investors in a research note.
Stephens
Overweight -> Equal Weight
downgrade
$150 -> $135
2025-06-03
Reason

Valuation Metrics

The current forward P/E ratio for Blueprint Medicines Corp (BPMC.O) is -173.16, compared to its 5-year average forward P/E of -24.76. For a more detailed relative valuation and DCF analysis to assess Blueprint Medicines Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-24.76
Current PE
-173.16
Overvalued PE
8.97
Undervalued PE
-58.49

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-38.99
Current EV/EBITDA
-364.58
Overvalued EV/EBITDA
40.22
Undervalued EV/EBITDA
-118.20

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
17.79
Current PS
10.69
Overvalued PS
27.84
Undervalued PS
7.74

Financials

Annual
Quarterly
FY2025Q1
YoY :
+55.45%
149.41M
Total Revenue
FY2025Q1
YoY :
-47.88%
-41.09M
Operating Profit
FY2025Q1
YoY :
-99.44%
496.00K
Net Income after Tax
FY2025Q1
YoY :
-99.29%
0.01
EPS - Diluted
FY2025Q1
YoY :
-45.13%
-56.31M
Free Cash Flow
FY2025Q1
YoY :
+1.49%
98.12
Gross Profit Margin - %
FY2025Q1
YoY :
-82.38%
-26.85
FCF Margin - %
FY2025Q1
YoY :
-99.64%
0.33
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.9M
USD
7
3-6
Months
4.4M
USD
10
6-9
Months
6.8M
USD
12
0-12
Months
2.4M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 135.09% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
291.8K
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
7
3.5M
Volume
Months
6-9
4
1.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

BPMC News & Events

Events Timeline

2025-06-12 (ET)
2025-06-12
18:02:31
Blueprint Medicines announces data reinforcing sustained efficacy of AYVAKIT
select
2025-06-02 (ET)
2025-06-02
07:37:41
Sanofi acquisition of Blueprint Medicines 'sensible,' says BofA
select
2025-06-02
05:44:53
Sanofi acquires Blueprint Medicines for $129 per share or $9.1B
select
Sign Up For More Events

News

8.5
07-22Benzinga
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
3.0
07-20NASDAQ.COM
BPMC Quantitative Stock Analysis
4.5
07-17NASDAQ.COM
After Hours Most Active for Jul 16, 2025 : SRPT, NVDA, AAPL, BPMC, PFE, QQQ, INTC, CNH, GE, NI, WFC, F
Sign Up For More News

FAQ

arrow icon

What is Blueprint Medicines Corp (BPMC) stock price today?

The current price of BPMC is 129.5 USD — it has increased 0.14 % in the last trading day.

arrow icon

What is Blueprint Medicines Corp (BPMC)'s business?

arrow icon

What is the price predicton of BPMC Stock?

arrow icon

What is Blueprint Medicines Corp (BPMC)'s revenue for the last quarter?

arrow icon

What is Blueprint Medicines Corp (BPMC)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Blueprint Medicines Corp (BPMC)'s fundamentals?

arrow icon

How many employees does Blueprint Medicines Corp (BPMC). have?

arrow icon

What is Blueprint Medicines Corp (BPMC) market cap?